Multicenter Transplant Study for Fanconi Anemia

The trial proposed is a single arm phase II multicenter treatment protocol designed to
examine engraftment, toxicity, graft-versus-host disease, and ultimate disease-free survival
following a novel cytoreductive regimen including busulfan, cyclophosphamide and fludarabine
and ATG (Anti-thymocyte globulin)for the treatment of patients with Fanconi anemia who have
severe aplastic anemia (SAA), or myelodysplastic syndrome(MDS) or acute myelogenous leukemia
(AML), lacking HLA-genotypically (HLA = human leukocyte antigen) identical donors using stem
cell transplants derived from HLA-compatible unrelated donors or HLA haplotype-mismatched
related donors using Miltenyi's CliniMACS.

Inclusion Criteria:

- Confirmed Diagnosis of Fanconi Anemia

- One of the following:Severe Aplastic Anemia or Severe Single Lineage Cytopenia;
Myelodysplastic Syndrome; Acute Myelogenous Leukemia

- Unrelated and Related Donors

- Adequate Physical Function (Cardiac, Hepatic, Renal, Pulmonary)

- Available for Long-Term Follow Up

- Performance status >= 70%

Exclusion Criteria:

- Co-existing medical problems that increase the risk of transplant

- Active CNS (central nervous system) leukemic involvement

- Pregnant or Breastfeeding (Females)

- Active, Uncontrolled Infection

- HIV/HTLV (Human T-lymphotropic virus)Positive